Is VNDA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

607 people get VNDA articles and Market Currents by email alert.

Get email alerts on VNDA »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Vanda Pharmaceuticals: A Small-Cap Biotech With A Pipeline Allowing For Long-Term Growth
Alexander Maxwell • Thu, Jun 6 • 3 Comments
Why Did Vanda Pharmaceuticals Hit A 52-Week High?
C.R. Jackson • Fri, Apr 19 • 5 Comments
As The Cash Burn At Vanda Pharmaceuticals Intensifies, All Eyes Are Now On The FDA
Matt Schilling • Fri, Jan 25 • 2 Comments
Cashed Up Biotech Vanda Could Keep On Falling
Praveen Jayarajan • Wed, Sep 5, 2012 • 7 Comments
4 Reasons To Buy This Biopharma For A Swan Song
Joe Springer • Fri, Aug 10, 2012 • 16 Comments
Vanda Pharmaceuticals: More Than Enough Cash On Hand To Buy Themselves
Scott Matusow • Wed, Aug 8, 2012 • 3 Comments
Vanda Pharma: Trading Below Cash With Upcoming Catalysts Expected 2H12
Mike Havrilla • Wed, Jun 13, 2012
Vanda Pharmaceuticals Trading Below Net Cash
Markus Aarnio • Mon, Mar 5, 2012 • 14 Comments
Vanda Pharmaceuticals: Absurdly Undervalued And Prime Buyout Target
DepthQuote • Tue, Dec 13, 2011 • 3 Comments
Vanda’s Pipeline Progresses
Zacks Investment Research • Sun, Aug 29, 2010 • 1 Comment
The Market Is Wrong About Vanda
Joseph Krueger • Mon, Jun 21, 2010 • 43 Comments
Vanda Pharmaceuticals: Heavily Undervalued
Penn Bioinvestor • Wed, Jul 8, 2009 • 4 Comments
Vanda Pharmaceuticals Comes Back from the Dead
Derek Lowe • Wed, Jul 1, 2009 • 2 Comments
SAC Capital Discloses Vanda Pharmaceuticals Stake
Market Folly • Thu, Jun 11, 2009
Vanda Pharmaceuticals: A Biotech Stock Worth Watching
VFC's Stock House • Wed, May 27, 2009 • 1 Comment
Vanda Pharma Surges on FDA Approval
ValueHuntr • Thu, May 7, 2009 • 1 Comment
Tang Capital Partners' Proxy Statement for Vanda Pharmaceuticals Calls for Liquidation
Greenbackd • Thu, Apr 9, 2009 • 1 Comment
Vanda's Schizophrenia Drug Goes Down for the Last Time
Derek Lowe • Wed, Jul 30, 2008 • 2 Comments
3 Positives From Vanda's Conference Call
Brett Scott • Thu, Oct 11, 2007 • 1 Comment
Vanda Pharmaceuticals: Finding Reassurance In Institutional Investors and Fair Value Calculations
Brett Scott • Mon, Aug 27, 2007

To learn more about Seeking Alpha Pro, click here.

Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market
Scott Matusow • Tue, Jun 18 • 28 Comments
Put Options Active On AmerisourceBergen
Interactive Brokers • Tue, Jun 11
5 Biotech Winners From Last Week With High Short Ratios
Heisenberg Principle • Mon, Dec 24, 2012
Stock Watch Wednesday, 19 December
VFC's Stock House • Wed, Dec 19, 2012 • 3 Comments
Weekly Stock Watch, Week Of 17 December
VFC's Stock House • Mon, Dec 17, 2012 • 12 Comments
4 Cash Loaded Biotech Stocks With Little Debt
ZetaKap • Thu, Aug 30, 2012 • 4 Comments
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts This Year
Markus Aarnio • Fri, Aug 10, 2012 • 7 Comments
Small Cap Bio-Pharma Movers For Wednesday August 8th
Scott Matusow • Wed, Aug 8, 2012 • 28 Comments
10 High-Growth Stocks Under $5 Undervalued By Levered Free Cash Flows
Kapitall • Thu, Jul 26, 2012
2 Pharmaceutical Companies Trading Below Net Cash - Part IV
Markus Aarnio • Mon, Jun 25, 2012 • 19 Comments
2 Pharmaceutical Companies Trading Below Net Cash
Markus Aarnio • Mon, May 21, 2012 • 2 Comments
Eli Lilly: 5% Dividend With A Chance For Capital Gains
Alexander J. Poulos • Thu, Apr 19, 2012 • 15 Comments
Top Micro Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 12 Comments
16 Biotech Stocks Sold Off By Hedge Funds
Kapitall • Mon, Apr 2, 2012 • 1 Comment
7 Stocks Unanimously Loved By Analysts
Davy Bui • Wed, Mar 7, 2012 • 12 Comments
6 Highly Liquid Biotech Stocks With Positive Correlation To Volatility
Kapitall • Tue, Jan 31, 2012
20 Biotech Stocks That Hedge Funds Are Selling
Kapitall • Sun, Dec 11, 2011 • 1 Comment
10 Buyout Candidates To Watch
VFC's Stock House • Mon, Nov 28, 2011 • 5 Comments
Biotech Focused Hedge Fund RA Capital's Top Q3 Picks
GuruFundPicks • Sun, Nov 20, 2011 • 3 Comments
Put Options To Consider For Portfolio Insurance
Value Research • Mon, Nov 7, 2011 • 1 Comment

Vanda Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Vanda Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Feb 12
Vanda Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012 • 1 Comment
Vanda Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
Vanda Pharmaceuticals, Inc. Q4 2009 Earnings Call Transcript
Tue, Feb 16, 2010
Vanda Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
Tue, Sep 2, 2008
Vanda Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
Thu, May 22, 2008
Vanda Pharmaceuticals Q4 2007 Earnings Call Transcript
Mon, Apr 7, 2008

Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder

PR Newswire (Mon, 7:00PM)
Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder

PR Newswire (Jun 5, 2013)
Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference

PR Newswire (May 31, 2013)
Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind

PR Newswire (May 31, 2013)
Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings

PR Newswire (May 30, 2013)
Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland

PR Newswire (May 23, 2013)
Vanda Pharmaceuticals Reports First Quarter 2013 Results

PR Newswire (May 9, 2013)
Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013

PR Newswire (Apr 18, 2013)
Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer

PR Newswire (Apr 17, 2013)
Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference

PR Newswire (Apr 4, 2013)
Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind

PR Newswire (Mar 25, 2013)
Vanda Withdraws Its Marketing Authorization Application For Fanaptum™ In The European Union

PR Newswire (Mar 14, 2013)
After-Hours Buzz: PAY, NTRI, PLL & More

at CNBC.com (Mar 5, 2013)
Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference

PR Newswire (Feb 27, 2013)
Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint

PR Newswire (Jan 31, 2013)
Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder

PR Newswire (Jan 23, 2013)
Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013

PR Newswire (Jan 22, 2013)
Vanda Announces Positive Phase III Results For Tasimelteon In The Treatment Of Non-24-Hour Disorder

PR Newswire (Dec 18, 2012)
Vanda Receives Negative Opinion from CHMP on Fanaptum™ for the Treatment of Schizophrenia

PR Newswire (Dec 13, 2012)
Vanda Pharmaceuticals Reports Third Quarter 2012 Results

PR Newswire (Nov 7, 2012)

VNDA vs. ETF Alternatives

Company Description

We are a biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with exclusive worldwide commercial rights to two product candidates in clinical development. We believe that each of our product... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 11, 3:21 PM Vanda Pharmaceuticals (VNDA +23.9%) soars after Baker Bros. more than doubles its position in the company from Q1. The hedge fund's stake now sits at 13.99%. A quick look at the options chain shows volume exceeded open interest at several strikes today for this months expiry. Comment! [Healthcare]
Tuesday, June 11, 12:45 PM Midday top 10 gainers: SGOC +56%. BEAT +53%. UQM +30%. PGNX +26%. DOLE +21%. NOA +21%. QCOR +20%. VNDA +19%. ALTI +13%. CMGE +13%.
Midday top 10 Losers: GNMK -23%. LULU -17%. SMA -16%. ALVR -15%. LDK -10%. PRIS -10%. RSOL -10%. IMUC -9%. ECTE -9%. COCO -9%. 1 Comment [On the Move]
Thursday, June 6, 8:03 AM Vanda Pharmaceuticals (VNDA) says that additional data from Phase III trials of the company's Tasimelteon treatment for Non-24-Hour Disorder "clearly demonstrate" that the medicine can train patients' master body clocks to the 24-hour day and that "continued treatment is necessary to maintain entrainment." Non-24-Hour Disorder affects most totally blind people. (PR) Comment! [Healthcare]
Wednesday, June 5, 9:15 AM Shares of Vanda Pharmaceuticals (VNDA) rise 2.36% premarket and look set to add to what has become quite a rally. The stock is up 109% over the past month, gathering momentum from analyst praise (I, II), positive commentary from the Tech Council of Maryland, and an NDA application for Tasimelteon. The company will present at the Jefferies Global Healthcare Conference tomorrow at 2:30. Comment! [Healthcare, On the Move]
Friday, May 31, 7:36 AM On the heels of yesterday's double-digit gains, Vanda Pharmaceuticals (VNDA) announces the submission of an NDA for Tasimelteon, which the company hopes can become the first FDA approved treatment for Non-24 hour disease in the totally blind. (PR) Comment! [Healthcare]
Friday, May 24, 12:45 PM Midday top 10 gainers: OTT +41%. ZIOP +25%. ESMC +18%. DRAM +17%. FCEL +17%. VNDA +17%. TNP +16%. BLDP +14%. BLOX +13%. VRTA +12%.
Midday top 10 Losers: DF -51%. RNIN -29%. ETAK -17%. SHLD -14%. HIHO -14%. HGSH -12%. PLM -11%. ANF -10%. TITN -10%. ARO -10%. 4 Comments [On the Move]
Friday, May 24, 12:32 PM Vanda Pharmaceuticals (VNDA +16.7%) pops today after the Tech Council of Maryland named the company Life Science Firm of the Year, outlining its encouraging research on tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder. The disorder is a rare condition that affects blind people, for which there are currently no FDA-approved drugs. Comment! [Healthcare, On the Move]
Friday, May 17, 12:45 PM Midday top 10 gainers: RSOL +60%. VNDA +23%. SCTY +19%. ORMP +16%. VSAT +16%. COCO +16%. NBG +14%. MHGC +13%. JRCC +13%. MVIS +12%.
Midday top 10 losers: ARUN -27%. UNXL -23%. COSI -14%. AFOP -12%. MNGA -12%. FSGI -10%. YOKU -10%. ALIM -9%. EGLE -9%. GIG -9%. Comment! [On the Move]
Friday, May 17, 10:51 AM Vanda Pharmaceuticals (VNDA +20%) pops after Lazard pounds the table on the stock and ups its price target by nearly 55% to a whopping $17 from $11. The firm cites positive checks from sleep specialists on tasimelteon for non-24 hour insomnia disorder. Comment! [Healthcare, On the Move]
Friday, May 10, 1:49 PM Vanda Pharmaceuticals (VNDA +1%) moves up after Jefferies raises its price target from $6 to $7, saying that a Tasimelteon filing is forthcoming. The firm notes that VNDA has plenty of cash to make it through potential Tasi approval, and it continues to develop market awareness and build pre-launch demand critical mass. Comment! [Healthcare, On the Move]
Thursday, May 9, 7:09 AM Vanda Pharmaceuticals (VNDA): Q1 EPS of -$0.15 beats by $0.10. Revenue of $8.1M misses by $0.32M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, May 9, 12:05 AM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
Wednesday, May 8, 5:30 PM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
Thursday, February 14, 1:46 PM Vanda Pharmaceuticals (VNDA +2.4%) moves up after Jefferies raised its rating to Buy on the shares earlier today, and ups its price target from $3.50 to $6.00. The firm cites surprisingly good Phase 3 data for Tasimelteon, noting that even the drugs conservatively discounted contribution is likely to have a big upside from current negative EV level. Comment! [Healthcare, On the Move]
Tuesday, February 12, 12:05 AM Notable earnings before Tuesday’s open: AB, AVP, DBD, FIS, FOSL, GT, HCP, HERO, HUN, KO, KORS, LVLT, MHP, MMC, OHI, OMC, RAI, SPR, TGH, TRP, UTHR, VAL, VNDA Comment! [Earnings]
Monday, February 11, 5:30 PM Notable earnings before Tuesday’s open: AB, AVP, DBD, FIS, FOSL, GT, HCP, HERO, HUN, KO, KORS, LVLT, MHP, MMC, OHI, OMC, RAI, SPR, TGH, TRP, UTHR, VAL, VNDA Comment! [Earnings]

anomaly1
Took profits $VNDA 12.50
Jun 11, 5:07 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
$VNDA - 88% Barchart technial buy signals - 18 new highs and up 22.46% in the last month - Relative strength Index 74.52%
May 3, 3:56 PM
Reply (1)

• !Report Abuse
View all 1 replies
smucelli: Thanks for info! Will watch.
May 4, 1:50 AM
• !Report Abuse
Add a reply...

140 characters

Michael Webb
$VNDA Those of you who initiated long positions in March are the real winners but Vanda will appreciate steadily through Q1 of 2014.
Apr 19, 6:43 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch Wednesday - $DDD, $SSYS, $HP, $ONVO.PK, $PFE, $UTHR, $VNDA, $NVS, $HEB http://bit.ly/cAHZ42
12/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch - $AAPL, $BBRY, $AMRN, $VNDA, $TTNP, $FCEL, $CPST, $GE, $C, $TROV, $NVC, $D ... http://bit.ly/cAHZ42
12/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
$TTNP.OB - Back in the ball game $VNDA -http://bit.ly/UjJ7KW
9/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
$TTNP - Back in the ball game $VNDA - http://bit.ly/UjJ7KW
9/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Cash Loaded Biotech Stocks With Little Debt http://bit.ly/NYQlHb $CYCC $OMPI $SSRX $VNDA @ZetaKap
8/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joe Springer
#biotech #pharma #stocks $VNDA $LLY $PPHM $GHDX $SCLN $AMRN $CRTX $NVS Vanda looks like a buy here: http://seekingalpha.com/a/h3pb
8/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$VNDA is my new pick. GL!
8/8/12
Reply (2)

• !Report Abuse
View all 2 replies
jan2948: On what DD are you making this call?
8/9/12
• !Report Abuse
yepok: dd is included in his article
8/9/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Jim Van Meerten
$VNDA - 88% Barchart technial buy signals - 18 new highs and up 22.46% in the last month - Relative strength Index 74.52%
May 3, 3:56 PM
Reply (1)

• !Report Abuse
View all 1 replies
smucelli: Thanks for info! Will watch.
May 4, 1:50 AM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$VNDA is my new pick. GL!
8/8/12
Reply (2)

• !Report Abuse
View all 2 replies
jan2948: On what DD are you making this call?
8/9/12
• !Report Abuse
yepok: dd is included in his article
8/9/12
• !Report Abuse
Add a reply...

140 characters

VNDA Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.